Key Highlights

  • Jaguar Health (NASDAQ:JAGX) traded near USD 0.82, down about 49%, on November 2, 2026. That implies a prior close near USD 1.62, simple arithmetic on two published numbers.
  • On that date every Series R preferred share, paid as a one-for-one dividend, converted automatically into 5 common shares, capped at 11,625,000 conversion shares in total, per the company's 8-K.
  • The Series R Dividend had a Record Date of October 13, an ex-dividend date of October 16 and payment on October 15, 2026, per the October 28 filing for Jaguar Health (NASDAQ:JAGX).
  • A special stockholder meeting is set for November 6, 2026, with a proposal to expand the Equity plan share reserve six-fold if approved, following the October 22 shelf filing.

The Series R Dividend and Its Conversion

On October 2, 2026, Jaguar Health (NASDAQ:JAGX) announced a one-time dividend of one Series R preferred share for each common share, including shares underlying certain warrants. The certificate designated 2,325,000 shares. Each Series R share converts automatically into 5 common shares on November 2, 2026, subject to a 19.99% beneficial ownership cap, and carries no dividend or voting rights and a Liquidation preference of USD 0.0001 per share. Paid on October 15 to holders of record on October 13, the dividend turned into new common stock on the very day the stock fell about 49%, though the company has not attributed the move to the conversion.

Why Conversions Can Pressure the Stock

When preferred stock converts into common, the number of common shares in the market rises while the company's value does not change, so each share represents a smaller slice. New shares reach holders who may sell, which adds supply. Jaguar Health (NASDAQ:JAGX) also asked C/M Capital, the Series P holder, to consent to the dividend, agreeing to repurchase those shares in cash if a Fundamental Transaction occurs. The October 5 filing shows Royalty interests of USD 12 million original principal each, whose first monthly payments of at least USD 750,000 were pushed from October 1, 2026 to January 1, 2027, and a USD 6,220,812.50 note extended to the same date.

Risks and Dates to Watch

At under USD 1 the stock is exposed to Nasdaq minimum bid rules, further equity issuance and a possible reverse split, none of which the October 28 filing announces. With a price this low, a small number of trades can move the quote, spreads can be wide and a quoted drop or bounce can reverse. The company filed an S-3 on October 22, 2026, and its November 6 meeting will decide the plan share reserve. The deferred royalty payments resume on January 1, 2027, which is a cash obligation to watch. Quarterly results and any financing news would add evidence.

Where Things Stand

The best-supported answer is that the 49% drop coincided with the November 2 conversion of Series R preferred into five common shares each, a mechanical increase in supply, though Jaguar Health (NASDAQ:JAGX) has not said so. Other pressure points include deferred royalty payments to January 1, 2027 and an October 22 shelf filing. Next dates are the November 6 meeting and any financing or Nasdaq notice.